Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.

Gillis J, Loutfy M, Bayoumi AM, Antoniou T, Burchell AN, Walmsley S, Cooper C, Klein MB, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Hogg R, Raboud J; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):531-539.

2.

Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.

Cescon A, Patterson S, Davey C, Ding E, Raboud JM, Chan K, Loutfy MR, Cooper C, Burchell AN, Palmer AK, Tsoukas C, Machouf N, Klein MB, Rourke SB, Rachlis A, Hogg RS, Montaner JS; CANOC Collaboration.

J Int AIDS Soc. 2015 Oct 5;18:20024. doi: 10.7448/IAS.18.1.20024. eCollection 2015.

3.

Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.

Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, Burchell AN, Cooper C, Klein MB, Rourke SB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS; CANOC collaboration.

BMC Infect Dis. 2015 Jul 17;15:274. doi: 10.1186/s12879-015-0969-x.

4.

Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history.

Cescon A, Chan K, Raboud JM, Burchell AN, Forrest JI, Klein MB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Cooper C; CANOC Collaboration.

AIDS. 2014 Jan 2;28(1):121-7. doi: 10.1097/QAD.0000000000000020.

PMID:
24413263
5.

Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in Canada: a multisite cohort study.

Cescon A, Patterson S, Chan K, Palmer AK, Margolese S, Burchell AN, Cooper C, Klein MB, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Raboud JM, Loutfy MR; CANOC Collaboration.

PLoS One. 2013 Dec 31;8(12):e83649. doi: 10.1371/journal.pone.0083649. eCollection 2013.

6.

Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada.

Palmer AK, Cescon A, Chan K, Cooper C, Raboud JM, Miller CL, Burchell AN, Klein MB, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Loutfy MR; CANOC Collaboration.

J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):56-62. doi: 10.1177/2325957413510606. Epub 2013 Dec 5.

PMID:
24309754
7.

Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration.

PLoS One. 2013 Oct 30;8(10):e77665. doi: 10.1371/journal.pone.0077665. eCollection 2013.

8.

Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.

Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, Machouf N, Montaner JS, Rourke S, Tsoukas C, Hogg B, Raboud J; CANOC Collaboration.

J Infect Dis. 2012 Apr 15;205(8):1230-8. doi: 10.1093/infdis/jis104.

9.

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.

PMID:
21709570
10.

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.

Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, Milan D, Shen A, Klein MB, Cooper C, Machouf N, Rourke SB, Rachlis A, Tsoukas C, Montaner JS, Walmsley SL, Smieja M, Bayoumi A, Mills E, Hogg RS; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):451-9.

PMID:
21105259
11.

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration.

HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8.

12.

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.

Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration.

BMC Infect Dis. 2010 Feb 25;10:40. doi: 10.1186/1471-2334-10-40.

13.

Cohort profile: the Canadian Observational Cohort collaboration.

Palmer AK, Klein MB, Raboud J, Cooper C, Hosein S, Loutfy M, Machouf N, Montaner J, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS; CANOC Collaboration.

Int J Epidemiol. 2011 Feb;40(1):25-32. doi: 10.1093/ije/dyp393. Epub 2010 Feb 15. No abstract available.

PMID:
20157000

Supplemental Content

Loading ...
Support Center